Thoratec Corp.  (THOR) Trade Now »     Rate THOR  -  Discuss THOR  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

THOR: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

FDA Calendar Updates: NeurogesX, Thoratec THOR

73%

+21.01% in 109 days <> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 288 entries as of 8/5/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, ANDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage cli... Continue reading »

FDA, Clinical Trial Calendar Updates: THOR, ALTH THOR

73%

-8.22% in 107 days (closed on 08/05/09) Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars .   <> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete r... Continue reading »

Bullish on THOR ... THOR

73%

+2.01% in 72 days (closed on 04/20/09) Healthcare Investing Trends for '09 and Beyond <> While the departure of Tom Daschle and concerns over rising unemployment and the global economic slowdown may hamper many of President Obama's plans for healthcare reform; there are several growth trends within the sector outlined below which are poised to benefit in 2009 and beyond. Follow any of the links below for more information on the new ETF Innovators indexes and exchange-traded fund ideas for the sector. Global Health IT : The top five rated companies include Swiss telemedicine firm Card Guard (CDGUF) – a pro< />< />< />< /><>< />< />< />< /><><>< />< /><>< />< />< />< /><>... Continue reading »

A New Global Healthcare Composite Index THOR

73%

-12.39% in 25 days (closed on 02/07/09) A New Global Healthcare Composite Index <> The accompanying table [click to enlarge] presents the top five rated companies with market caps of at least $100M from each of the eight new ETF Innovators healthcare indexes, including a database exceeding 500 companies worldwide. The Healthcare Composite Index is a dynamic, semi-active index with quarterly rebalancing which consists of the 40 top-rated companies on an equal weight basis from each of the eight global healthcare indexes listed below and represents an alternative strategy to existing health composite ETF... Continue reading »

A New Index of Health Product Innovators THOR

73%

-7.95% in 8 days (closed on 01/13/09) A New Index of Health Product Innovators <> The accompanying table includes statistics and all 23 companies in the ETF Innovators [ETFI] Global Health Innovators Index of companies with market caps over $250M which received FDA approval in the past 12 months for an original new drug product or medical device. The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding all new formulations of existing drugs, generic drugs, and label extensions for existing products). Also, companies whi... Continue reading »

From the Blogosphere

The 'Micropsia' Group: 8 Healthcare Stocks Bullish in Some Time Frame

<>The micropsia sequence of posts was not really fair, mostly because I revealed few items, if any [click links for posts, in order]. But now has come the moment to reveal several items. First, the companies (in order of presentation)... 1) BioDelivery Sciences (BDSI) 2) Spectrum Pharmaceuticals (SPPI) 3) OncoGenex Pharmaceuticals (OGXI) 4) Vion Pharmaceuticals (VION) 5) Isis Pharmaceuticals (ISIS) 6) Johnson & Johnson (JNJ) 7) Volcano (VOLC) 8) Thoratec (THOR) You will discern rather quickly my second 'revelation' -- the obvious fact that all eight companies derive from one key market sector, health ... Continue reading »

Bookkeeping: Stopped out of Thoratec (THOR) Short; Into Darden (DRI)

34%

That was a quick visit to the short side on Thoratec (THOR) - as we mentioned yesterday healthcare has seen an immense rotation into it particulary this week as computers left the reflation trade to the new flavor of the (day?) (week?) (month?). Thoratec has been a long for us for a long time, but when it broke support we exited... We shorted it Wednesday <><>I am short Thoratec (THOR) for technical reasons only (I like the story if not the valuation) - the stock is actually up today go figure... so my limit order to short at $25.50 hit just a few minutes ago. That is the 20 day <>moving <nobr sty... Continue reading »

Bookkeeping: Short Thoratec (THOR)

34%

I am short Thoratec (THOR) for technical reasons only (I like the story if not the valuation) - the stock is actually up today go figure... so my limit order to short at $25.50 hit just a few minutes ago. That is the 20 day moving average - the 50 day is $25.80, and the 200 day is $26.20. My stop loss will be $26.35 where I'll exit out. This is about a 3% position. I am however shaking my head at myself right now, so many missed trades - I had shorted Sherwin Williams (SHW) a few weeks ago, and the day I posted that trade I said I could of chosen Royal Carribean (RCL) or Black & Decker (BKD)... Continue reading »

ETF Screener: Sarah Palin Can See Japan From Her House Too

49%

Small-cap Japanese ETFs lead the way in new buy signals in this week’s ETF screener. When three different ETFs produce the same technical analysis buy signal, you have to take the confirmation seriously - especially when each is managed by a different firm. This tells us the style is the driving force behind the buy signals and not an individual ETFs particular stock picking methodology. Investors looking for international exposure might consider these international ETFs. <> iShares MSCI Japan Small Cap Index (SCJ) SPDR Russell/Nomura Small Cap Japan (JSC) <>WisdomTree Japan SmallCap Dividend (... Continue reading »

Bookkeeping: Closing Thoratec (THOR)

34%

As I perused charts this weekend looking for new ideas, I saw a limited amount of stocks below their 20, 50, and 200 day moving averages. For well traded stocks (200K daily volume) over $10, with a market cap over $300M... there were less than 200 - unfortunately a few are sitting on our sheets. Thoratec (THOR) is one of them, and we see some quite extreme weakness after a very rosy earnings report. So I am going to let the charts decide this one and close the last smallish piece of the long position - we only had a 0.4% stake remaining. While I questioned the valuation post earnings [<>Ma... Continue reading »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.